Integra LifeSciences Holdings Corp. (NASDAQ:IART) shares hit a new 52-week high during trading on Thursday . The stock traded as high as $85.45 and last traded at $85.41, with a volume of 102,560 shares traded. The stock had previously closed at $84.67.

IART has been the subject of several recent analyst reports. Zacks Investment Research raised Integra LifeSciences Holdings Corp. from a “hold” rating to a “buy” rating and set a $79.00 price objective for the company in a report on Monday, May 2nd. Jefferies Group reaffirmed a “buy” rating on shares of Integra LifeSciences Holdings Corp. in a research note on Thursday, April 28th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of Integra LifeSciences Holdings Corp. in a research note on Thursday, April 28th. Barclays PLC upped their target price on Integra LifeSciences Holdings Corp. from $77.00 to $84.00 and gave the stock an “equal weight” rating in a research note on Friday, July 29th. Finally, Lake Street Capital upped their target price on Integra LifeSciences Holdings Corp. from $57.00 to $75.00 and gave the stock a “hold” rating in a research note on Thursday, April 28th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Integra LifeSciences Holdings Corp. has an average rating of “Buy” and a consensus target price of $81.75.

The company’s 50-day moving average price is $82.04 and its 200 day moving average price is $71.46. The firm has a market capitalization of $3.21 billion and a P/E ratio of 354.50.

Integra LifeSciences Holdings Corp. (NASDAQ:IART) last issued its earnings results on Thursday, July 28th. The company reported $0.79 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.76 by $0.03. During the same period last year, the firm earned $0.79 earnings per share. The firm had revenue of $249.30 million for the quarter, compared to the consensus estimate of $243.17 million. The company’s revenue for the quarter was up 17.2% on a year-over-year basis. Analysts expect that Integra LifeSciences Holdings Corp. will post $3.48 EPS for the current year.

In other news, Director Raymond G. Murphy sold 2,610 shares of the company’s stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $84.83, for a total value of $221,406.30. Following the sale, the director now owns 33,057 shares in the company, valued at $2,804,225.31. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Peter J. Arduini sold 24,009 shares of the company’s stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $84.52, for a total value of $2,029,240.68. Following the completion of the sale, the chief executive officer now owns 29,602 shares in the company, valued at approximately $2,501,961.04. The disclosure for this sale can be found here.

Several hedge funds recently modified their holdings of IART. State of Tennessee Treasury Department bought a new stake in shares of Integra LifeSciences Holdings Corp. during the fourth quarter worth approximately $1,501,000. Principal Financial Group Inc. increased its stake in shares of Integra LifeSciences Holdings Corp. by 7.0% in the fourth quarter. Principal Financial Group Inc. now owns 196,763 shares of the company’s stock worth $13,337,000 after buying an additional 12,904 shares during the last quarter. Westfield Capital Management Co. LP increased its stake in shares of Integra LifeSciences Holdings Corp. by 41.7% in the fourth quarter. Westfield Capital Management Co. LP now owns 432,445 shares of the company’s stock worth $29,311,000 after buying an additional 127,170 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of Integra LifeSciences Holdings Corp. by 1.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 928,232 shares of the company’s stock worth $62,916,000 after buying an additional 11,339 shares during the last quarter.

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.